Voyager Therapeutics
NEWS
Voyager Therapeutics released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease.
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease.
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.
JOBS
IN THE PRESS